Comments
Shares of Aurobindo Pharma crashed over 20 per cent on Monday, following the US drug regulator's adverse observation.
After hitting a year low of ₹450.35, the stock ended the day at ₹451.70, down 20.41 per cent, on the NSE.
The USFDA has issued a note (after inspecting Aurobindo’s Unit-7 between September 19-27, 2019) indicating procedural lapses along with lack of Quality control.
The USFDA observations are as follows: Failure to review any unexplained discrepancy; failure to consider failure of batch or components; Control procedures not established; No written procedures for production and process controls; Equipment and utensils not cleaned at appropriate levels; Procedures applicable to Quality control not thoroughly followed; and written production and process controls not developed in execution of production, process controls.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.